(Logo via Johnson & Johnson)

Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis

Originally Published on JNJ.com  

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive top-line results from the Phase 3 OPTIMUM study, which evaluated the efficacy and safety of ponesimod compared to Aubagio®* (teriflunomide) in adults with relapsing multiple sclerosis. The study met its primary and most secondary endpoints.

Ponesimod is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, a class of drugs that is believed to functionally inhibit S1P activity and reduce the number of circulating lymphocytes by trapping them in the lymph nodes. Therefore, there are less inflammatory cells available to cross into the central nervous system (CNS) where they could damage myelin. Myelin is a protective sheath that insulates nerve cells and is damaged in patients with multiple sclerosis.[i]

The primary endpoint of OPTIMUM was annualized relapse rate (ARR) up to the end of the study. A key secondary endpoint was change from baseline to week 108 in fatigue-related symptoms. Fatigue is considered a significant unmet need from patients’ perspective. Additionally, the study evaluated other secondary endpoints: cumulative number of combined unique active lesions (CUALs) using magnetic resonance imaging (MRI), time to first 12-week confirmed disability accumulation (CDA) and time to first 24-week CDA from baseline to end of the study.

The safety profile observed for ponesimod in the OPTIMUM study was consistent with previous studies of ponesimod, and the known safety profile for other S1P receptor modulators.

OPTIMUM was a head-to-head, prospective, multicenter, randomized, double-blind, active controlled, parallel-group, Phase 3 superiority study to compare efficacy, safety and tolerability of ponesimod 20 mg versus teriflunomide 14 mg in adults with relapsing multiple sclerosis. The study included 1,133 participants with the treatment duration of 108 weeks.

Data from the OPTIMUM study have been accepted for presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019.

Data from the OPTIMUM study will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of ponesimod as a treatment for relapsing forms of multiple sclerosis, which are anticipated for later this year.

 

Latest News

Census 2020 map

Biden Administration Exploring Policy Changes To Make US Census More Accurate and Inclusive of Race and Ethnicity

President Biden and the U.S. Census Bureau are hoping to revive a previously proposed policy that would allow the 2030 survey to ask more accurate questions about race and ethnicity — and by extension, improve the quality of demographic data acquired and used toward policymaking, voting districts, and enforcing civil…

Rep. Joyce Beatty

Rep. Joyce Beatty and Voting Rights Activists Arrested During Peaceful Protest in Senate Building

Protests continue across the nation’s capital in an effort to rein in racist anti-voter legislation taking place in states such as Texas, Florida, and Georgia. And now, those efforts have progressed to the level where elected officials are getting arrested for supporting every American citizen’s right to fairly and legally…

United States Capitol building

New Study Shows Historic Diversity and Inclusion Within Senate Democrats’ Staffing and Workforce

Elected and federally appointed officials aren’t the only ones making government more diverse and inclusive. A new government survey has revealed that more than 38% of people working on the Democratic side of the Senate also identify as non-Caucasian. CNN’s Daniella Diaz and Ali Zaslav have reported on the survey,…